MYC and cancer: Aprepitant downregulates the expression of lymphoid enhancer-binding factor 1, c-myc and cyclin D1; arrests the G2 cell cycle leading to apoptosis in cancer cells; impairs the interaction of beta-catenin with Forkhead box M1 promoting the inhibition of the Wnt canonical pathway (which decreases super TOP/FOP and increases membrane stabilization of beta-catenin), and exerts an antitumor action (Figure 1) [20,84].